nodes	percent_of_prediction	percent_of_DWPC	metapath
Lidocaine—osteoarthritis—Prednisone—psoriasis	0.38	1	CpDpCtD
Lidocaine—CYP2A6—Methoxsalen—psoriasis	0.0339	0.0803	CbGbCtD
Lidocaine—CYP2C8—Tazarotene—psoriasis	0.0259	0.0614	CbGbCtD
Lidocaine—CYP3A5—Beclomethasone—psoriasis	0.0251	0.0594	CbGbCtD
Lidocaine—CYP1A2—Clobetasol propionate—psoriasis	0.0246	0.0583	CbGbCtD
Lidocaine—CYP2A6—Prednisolone—psoriasis	0.0165	0.039	CbGbCtD
Lidocaine—CYP2B6—Cholecalciferol—psoriasis	0.0146	0.0346	CbGbCtD
Lidocaine—CYP1A2—Methoxsalen—psoriasis	0.0129	0.0306	CbGbCtD
Lidocaine—CYP2D6—Hydroxyurea—psoriasis	0.0117	0.0276	CbGbCtD
Lidocaine—CYP2C8—Cholecalciferol—psoriasis	0.0111	0.0262	CbGbCtD
Lidocaine—CYP3A7—Hydrocortisone—psoriasis	0.0107	0.0253	CbGbCtD
Lidocaine—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0107	0.0253	CbGbCtD
Lidocaine—CYP3A7—Cyclosporine—psoriasis	0.0101	0.0239	CbGbCtD
Lidocaine—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0101	0.0239	CbGbCtD
Lidocaine—CYP3A5—Mycophenolate mofetil—psoriasis	0.00999	0.0237	CbGbCtD
Lidocaine—CYP2A6—Dexamethasone—psoriasis	0.00972	0.023	CbGbCtD
Lidocaine—CYP2C8—Mycophenolate mofetil—psoriasis	0.0096	0.0227	CbGbCtD
Lidocaine—CYP3A4—Calcitriol—psoriasis	0.00872	0.0206	CbGbCtD
Lidocaine—CYP3A5—Hydrocortisone—psoriasis	0.00801	0.019	CbGbCtD
Lidocaine—CYP2C9—Cholecalciferol—psoriasis	0.00772	0.0183	CbGbCtD
Lidocaine—CYP2C8—Hydrocortisone—psoriasis	0.00771	0.0182	CbGbCtD
Lidocaine—CYP3A5—Cyclosporine—psoriasis	0.00757	0.0179	CbGbCtD
Lidocaine—CYP2C8—Cyclosporine—psoriasis	0.00728	0.0172	CbGbCtD
Lidocaine—CYP2D6—Cholecalciferol—psoriasis	0.00706	0.0167	CbGbCtD
Lidocaine—CYP3A4—Methoxsalen—psoriasis	0.00678	0.0161	CbGbCtD
Lidocaine—CYP3A7—Dexamethasone—psoriasis	0.00664	0.0157	CbGbCtD
Lidocaine—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.00664	0.0157	CbGbCtD
Lidocaine—ABCB1—Mycophenolate mofetil—psoriasis	0.0065	0.0154	CbGbCtD
Lidocaine—CYP2B6—Dexamethasone—psoriasis	0.00633	0.015	CbGbCtD
Lidocaine—ABCB1—Betamethasone—psoriasis	0.00558	0.0132	CbGbCtD
Lidocaine—ABCB1—Prednisolone—psoriasis	0.0055	0.013	CbGbCtD
Lidocaine—ABCB1—Hydrocortisone—psoriasis	0.00522	0.0124	CbGbCtD
Lidocaine—ABCB1—Prednisone—psoriasis	0.0052	0.0123	CbGbCtD
Lidocaine—CYP2C9—Cyclosporine—psoriasis	0.00508	0.012	CbGbCtD
Lidocaine—CYP3A5—Dexamethasone—psoriasis	0.00498	0.0118	CbGbCtD
Lidocaine—ABCB1—Cyclosporine—psoriasis	0.00493	0.0117	CbGbCtD
Lidocaine—CYP2C8—Dexamethasone—psoriasis	0.00479	0.0113	CbGbCtD
Lidocaine—CYP2D6—Cyclosporine—psoriasis	0.00464	0.011	CbGbCtD
Lidocaine—CYP3A4—Cholecalciferol—psoriasis	0.00449	0.0106	CbGbCtD
Lidocaine—CYP3A4—Mycophenolate mofetil—psoriasis	0.00389	0.00922	CbGbCtD
Lidocaine—CYP3A4—Triamcinolone—psoriasis	0.00389	0.00922	CbGbCtD
Lidocaine—CYP2C9—Dexamethasone—psoriasis	0.00334	0.00792	CbGbCtD
Lidocaine—CYP3A4—Betamethasone—psoriasis	0.00334	0.00791	CbGbCtD
Lidocaine—CYP3A4—Prednisolone—psoriasis	0.0033	0.00781	CbGbCtD
Lidocaine—ABCB1—Dexamethasone—psoriasis	0.00324	0.00768	CbGbCtD
Lidocaine—CYP3A4—Hydrocortisone—psoriasis	0.00312	0.0074	CbGbCtD
Lidocaine—CYP3A4—Prednisone—psoriasis	0.00311	0.00737	CbGbCtD
Lidocaine—CYP2D6—Dexamethasone—psoriasis	0.00306	0.00724	CbGbCtD
Lidocaine—CYP3A4—Cyclosporine—psoriasis	0.00295	0.00699	CbGbCtD
Lidocaine—ABCB1—Methotrexate—psoriasis	0.00261	0.00617	CbGbCtD
Lidocaine—CYP3A4—Dexamethasone—psoriasis	0.00194	0.0046	CbGbCtD
Lidocaine—Convulsion—Mycophenolate mofetil—psoriasis	7.62e-05	0.000503	CcSEcCtD
Lidocaine—Hypertension—Mycophenolate mofetil—psoriasis	7.59e-05	0.000501	CcSEcCtD
Lidocaine—Visual impairment—Betamethasone—psoriasis	7.58e-05	0.0005	CcSEcCtD
Lidocaine—Visual impairment—Dexamethasone—psoriasis	7.58e-05	0.0005	CcSEcCtD
Lidocaine—Erythema—Triamcinolone—psoriasis	7.54e-05	0.000498	CcSEcCtD
Lidocaine—Angioedema—Prednisolone—psoriasis	7.5e-05	0.000494	CcSEcCtD
Lidocaine—Feeling abnormal—Mycophenolic acid—psoriasis	7.49e-05	0.000494	CcSEcCtD
Lidocaine—Chest pain—Mycophenolate mofetil—psoriasis	7.49e-05	0.000494	CcSEcCtD
Lidocaine—Neuropathy peripheral—Prednisone—psoriasis	7.48e-05	0.000493	CcSEcCtD
Lidocaine—Anxiety—Mycophenolate mofetil—psoriasis	7.46e-05	0.000492	CcSEcCtD
Lidocaine—Confusional state—Cyclosporine—psoriasis	7.42e-05	0.000489	CcSEcCtD
Lidocaine—Dysgeusia—Triamcinolone—psoriasis	7.39e-05	0.000487	CcSEcCtD
Lidocaine—Oedema—Cyclosporine—psoriasis	7.36e-05	0.000485	CcSEcCtD
Lidocaine—Anaphylactic shock—Cyclosporine—psoriasis	7.36e-05	0.000485	CcSEcCtD
Lidocaine—Eye disorder—Betamethasone—psoriasis	7.35e-05	0.000485	CcSEcCtD
Lidocaine—Eye disorder—Dexamethasone—psoriasis	7.35e-05	0.000485	CcSEcCtD
Lidocaine—Angioedema—Hydrocortisone—psoriasis	7.32e-05	0.000483	CcSEcCtD
Lidocaine—Back pain—Triamcinolone—psoriasis	7.3e-05	0.000481	CcSEcCtD
Lidocaine—Confusional state—Mycophenolate mofetil—psoriasis	7.24e-05	0.000477	CcSEcCtD
Lidocaine—Nervous system disorder—Cyclosporine—psoriasis	7.22e-05	0.000476	CcSEcCtD
Lidocaine—Loss of consciousness—Prednisolone—psoriasis	7.21e-05	0.000476	CcSEcCtD
Lidocaine—Dizziness—Hydroxyurea—psoriasis	7.18e-05	0.000474	CcSEcCtD
Lidocaine—Anaphylactic shock—Mycophenolate mofetil—psoriasis	7.18e-05	0.000473	CcSEcCtD
Lidocaine—Oedema—Mycophenolate mofetil—psoriasis	7.18e-05	0.000473	CcSEcCtD
Lidocaine—Asthma—Methotrexate—psoriasis	7.15e-05	0.000472	CcSEcCtD
Lidocaine—Angiopathy—Dexamethasone—psoriasis	7.13e-05	0.000471	CcSEcCtD
Lidocaine—Angiopathy—Betamethasone—psoriasis	7.13e-05	0.000471	CcSEcCtD
Lidocaine—Hyperhidrosis—Cyclosporine—psoriasis	7.11e-05	0.000469	CcSEcCtD
Lidocaine—Convulsion—Prednisolone—psoriasis	7.11e-05	0.000469	CcSEcCtD
Lidocaine—Hypertension—Prednisolone—psoriasis	7.08e-05	0.000467	CcSEcCtD
Lidocaine—Shock—Mycophenolate mofetil—psoriasis	7.06e-05	0.000466	CcSEcCtD
Lidocaine—Loss of consciousness—Hydrocortisone—psoriasis	7.04e-05	0.000465	CcSEcCtD
Lidocaine—Nervous system disorder—Mycophenolate mofetil—psoriasis	7.04e-05	0.000464	CcSEcCtD
Lidocaine—Bradycardia—Prednisone—psoriasis	6.97e-05	0.00046	CcSEcCtD
Lidocaine—Convulsion—Hydrocortisone—psoriasis	6.94e-05	0.000458	CcSEcCtD
Lidocaine—Hyperhidrosis—Mycophenolate mofetil—psoriasis	6.94e-05	0.000458	CcSEcCtD
Lidocaine—Hypertension—Hydrocortisone—psoriasis	6.92e-05	0.000456	CcSEcCtD
Lidocaine—Vomiting—Hydroxyurea—psoriasis	6.9e-05	0.000455	CcSEcCtD
Lidocaine—Angioedema—Triamcinolone—psoriasis	6.89e-05	0.000455	CcSEcCtD
Lidocaine—Haemoglobin—Prednisone—psoriasis	6.88e-05	0.000454	CcSEcCtD
Lidocaine—Haemorrhage—Prednisone—psoriasis	6.85e-05	0.000452	CcSEcCtD
Lidocaine—Rash—Hydroxyurea—psoriasis	6.85e-05	0.000452	CcSEcCtD
Lidocaine—Erythema—Dexamethasone—psoriasis	6.84e-05	0.000452	CcSEcCtD
Lidocaine—Erythema—Betamethasone—psoriasis	6.84e-05	0.000452	CcSEcCtD
Lidocaine—Dermatitis—Hydroxyurea—psoriasis	6.84e-05	0.000451	CcSEcCtD
Lidocaine—Headache—Hydroxyurea—psoriasis	6.8e-05	0.000449	CcSEcCtD
Lidocaine—Anxiety—Hydrocortisone—psoriasis	6.8e-05	0.000448	CcSEcCtD
Lidocaine—Hypotension—Mycophenolate mofetil—psoriasis	6.71e-05	0.000442	CcSEcCtD
Lidocaine—Anaphylactic shock—Prednisolone—psoriasis	6.69e-05	0.000442	CcSEcCtD
Lidocaine—Oedema—Prednisolone—psoriasis	6.69e-05	0.000442	CcSEcCtD
Lidocaine—Loss of consciousness—Triamcinolone—psoriasis	6.63e-05	0.000437	CcSEcCtD
Lidocaine—Paraesthesia—Cyclosporine—psoriasis	6.61e-05	0.000436	CcSEcCtD
Lidocaine—Shock—Prednisolone—psoriasis	6.59e-05	0.000435	CcSEcCtD
Lidocaine—Dyspnoea—Cyclosporine—psoriasis	6.56e-05	0.000433	CcSEcCtD
Lidocaine—Somnolence—Cyclosporine—psoriasis	6.54e-05	0.000431	CcSEcCtD
Lidocaine—Anaphylactic shock—Hydrocortisone—psoriasis	6.54e-05	0.000431	CcSEcCtD
Lidocaine—Oedema—Hydrocortisone—psoriasis	6.54e-05	0.000431	CcSEcCtD
Lidocaine—Convulsion—Triamcinolone—psoriasis	6.54e-05	0.000431	CcSEcCtD
Lidocaine—Asthenia—Mycophenolic acid—psoriasis	6.52e-05	0.00043	CcSEcCtD
Lidocaine—Hypertension—Triamcinolone—psoriasis	6.51e-05	0.00043	CcSEcCtD
Lidocaine—Hyperhidrosis—Prednisolone—psoriasis	6.47e-05	0.000427	CcSEcCtD
Lidocaine—Nausea—Hydroxyurea—psoriasis	6.45e-05	0.000425	CcSEcCtD
Lidocaine—Paraesthesia—Mycophenolate mofetil—psoriasis	6.44e-05	0.000425	CcSEcCtD
Lidocaine—Shock—Hydrocortisone—psoriasis	6.43e-05	0.000424	CcSEcCtD
Lidocaine—Nervous system disorder—Hydrocortisone—psoriasis	6.41e-05	0.000423	CcSEcCtD
Lidocaine—Eye disorder—Prednisone—psoriasis	6.4e-05	0.000422	CcSEcCtD
Lidocaine—Dyspnoea—Mycophenolate mofetil—psoriasis	6.4e-05	0.000422	CcSEcCtD
Lidocaine—Somnolence—Mycophenolate mofetil—psoriasis	6.38e-05	0.000421	CcSEcCtD
Lidocaine—Drowsiness—Methotrexate—psoriasis	6.37e-05	0.000421	CcSEcCtD
Lidocaine—Flushing—Prednisone—psoriasis	6.36e-05	0.000419	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Cyclosporine—psoriasis	6.35e-05	0.000419	CcSEcCtD
Lidocaine—Hyperhidrosis—Hydrocortisone—psoriasis	6.32e-05	0.000417	CcSEcCtD
Lidocaine—Pain—Cyclosporine—psoriasis	6.29e-05	0.000415	CcSEcCtD
Lidocaine—Angioedema—Dexamethasone—psoriasis	6.25e-05	0.000413	CcSEcCtD
Lidocaine—Angioedema—Betamethasone—psoriasis	6.25e-05	0.000413	CcSEcCtD
Lidocaine—Stomatitis—Methotrexate—psoriasis	6.21e-05	0.00041	CcSEcCtD
Lidocaine—Angiopathy—Prednisone—psoriasis	6.21e-05	0.00041	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	6.2e-05	0.000409	CcSEcCtD
Lidocaine—Immune system disorder—Prednisone—psoriasis	6.19e-05	0.000408	CcSEcCtD
Lidocaine—Anaphylactic shock—Triamcinolone—psoriasis	6.16e-05	0.000406	CcSEcCtD
Lidocaine—Oedema—Triamcinolone—psoriasis	6.16e-05	0.000406	CcSEcCtD
Lidocaine—Pain—Mycophenolate mofetil—psoriasis	6.14e-05	0.000405	CcSEcCtD
Lidocaine—Hypotension—Hydrocortisone—psoriasis	6.11e-05	0.000403	CcSEcCtD
Lidocaine—Feeling abnormal—Cyclosporine—psoriasis	6.06e-05	0.0004	CcSEcCtD
Lidocaine—Shock—Triamcinolone—psoriasis	6.06e-05	0.0004	CcSEcCtD
Lidocaine—Loss of consciousness—Betamethasone—psoriasis	6.02e-05	0.000397	CcSEcCtD
Lidocaine—Loss of consciousness—Dexamethasone—psoriasis	6.02e-05	0.000397	CcSEcCtD
Lidocaine—Dizziness—Mycophenolic acid—psoriasis	6.01e-05	0.000397	CcSEcCtD
Lidocaine—Paraesthesia—Prednisolone—psoriasis	6.01e-05	0.000397	CcSEcCtD
Lidocaine—Erythema—Prednisone—psoriasis	5.96e-05	0.000393	CcSEcCtD
Lidocaine—Hyperhidrosis—Triamcinolone—psoriasis	5.95e-05	0.000393	CcSEcCtD
Lidocaine—Convulsion—Betamethasone—psoriasis	5.93e-05	0.000391	CcSEcCtD
Lidocaine—Convulsion—Dexamethasone—psoriasis	5.93e-05	0.000391	CcSEcCtD
Lidocaine—Feeling abnormal—Mycophenolate mofetil—psoriasis	5.91e-05	0.00039	CcSEcCtD
Lidocaine—Hypertension—Dexamethasone—psoriasis	5.91e-05	0.00039	CcSEcCtD
Lidocaine—Hypertension—Betamethasone—psoriasis	5.91e-05	0.00039	CcSEcCtD
Lidocaine—Paraesthesia—Hydrocortisone—psoriasis	5.87e-05	0.000387	CcSEcCtD
Lidocaine—Urticaria—Cyclosporine—psoriasis	5.84e-05	0.000386	CcSEcCtD
Lidocaine—Anxiety—Dexamethasone—psoriasis	5.81e-05	0.000383	CcSEcCtD
Lidocaine—Anxiety—Betamethasone—psoriasis	5.81e-05	0.000383	CcSEcCtD
Lidocaine—Vomiting—Mycophenolic acid—psoriasis	5.78e-05	0.000381	CcSEcCtD
Lidocaine—Haemoglobin—Methotrexate—psoriasis	5.75e-05	0.000379	CcSEcCtD
Lidocaine—Rash—Mycophenolic acid—psoriasis	5.73e-05	0.000378	CcSEcCtD
Lidocaine—Dermatitis—Mycophenolic acid—psoriasis	5.73e-05	0.000378	CcSEcCtD
Lidocaine—Pain—Prednisolone—psoriasis	5.73e-05	0.000378	CcSEcCtD
Lidocaine—Haemorrhage—Methotrexate—psoriasis	5.72e-05	0.000378	CcSEcCtD
Lidocaine—Urticaria—Mycophenolate mofetil—psoriasis	5.7e-05	0.000376	CcSEcCtD
Lidocaine—Headache—Mycophenolic acid—psoriasis	5.7e-05	0.000376	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Hydrocortisone—psoriasis	5.65e-05	0.000372	CcSEcCtD
Lidocaine—Vision blurred—Prednisone—psoriasis	5.62e-05	0.000371	CcSEcCtD
Lidocaine—Pain—Hydrocortisone—psoriasis	5.59e-05	0.000369	CcSEcCtD
Lidocaine—Anaphylactic shock—Dexamethasone—psoriasis	5.59e-05	0.000369	CcSEcCtD
Lidocaine—Oedema—Dexamethasone—psoriasis	5.59e-05	0.000369	CcSEcCtD
Lidocaine—Anaphylactic shock—Betamethasone—psoriasis	5.59e-05	0.000369	CcSEcCtD
Lidocaine—Oedema—Betamethasone—psoriasis	5.59e-05	0.000369	CcSEcCtD
Lidocaine—Paraesthesia—Triamcinolone—psoriasis	5.53e-05	0.000365	CcSEcCtD
Lidocaine—Feeling abnormal—Prednisolone—psoriasis	5.52e-05	0.000364	CcSEcCtD
Lidocaine—Visual impairment—Methotrexate—psoriasis	5.52e-05	0.000364	CcSEcCtD
Lidocaine—Shock—Dexamethasone—psoriasis	5.5e-05	0.000363	CcSEcCtD
Lidocaine—Shock—Betamethasone—psoriasis	5.5e-05	0.000363	CcSEcCtD
Lidocaine—Dyspnoea—Triamcinolone—psoriasis	5.49e-05	0.000362	CcSEcCtD
Lidocaine—Nervous system disorder—Dexamethasone—psoriasis	5.48e-05	0.000361	CcSEcCtD
Lidocaine—Nervous system disorder—Betamethasone—psoriasis	5.48e-05	0.000361	CcSEcCtD
Lidocaine—Agitation—Prednisone—psoriasis	5.48e-05	0.000361	CcSEcCtD
Lidocaine—Angioedema—Prednisone—psoriasis	5.45e-05	0.000359	CcSEcCtD
Lidocaine—Hypersensitivity—Cyclosporine—psoriasis	5.42e-05	0.000358	CcSEcCtD
Lidocaine—Nausea—Mycophenolic acid—psoriasis	5.4e-05	0.000356	CcSEcCtD
Lidocaine—Hyperhidrosis—Betamethasone—psoriasis	5.4e-05	0.000356	CcSEcCtD
Lidocaine—Hyperhidrosis—Dexamethasone—psoriasis	5.4e-05	0.000356	CcSEcCtD
Lidocaine—Feeling abnormal—Hydrocortisone—psoriasis	5.39e-05	0.000355	CcSEcCtD
Lidocaine—Eye disorder—Methotrexate—psoriasis	5.35e-05	0.000353	CcSEcCtD
Lidocaine—Tinnitus—Methotrexate—psoriasis	5.34e-05	0.000352	CcSEcCtD
Lidocaine—Urticaria—Prednisolone—psoriasis	5.32e-05	0.000351	CcSEcCtD
Lidocaine—Cardiac disorder—Methotrexate—psoriasis	5.31e-05	0.00035	CcSEcCtD
Lidocaine—Hypersensitivity—Mycophenolate mofetil—psoriasis	5.29e-05	0.000349	CcSEcCtD
Lidocaine—Asthenia—Cyclosporine—psoriasis	5.28e-05	0.000348	CcSEcCtD
Lidocaine—Pain—Triamcinolone—psoriasis	5.26e-05	0.000347	CcSEcCtD
Lidocaine—Loss of consciousness—Prednisone—psoriasis	5.24e-05	0.000346	CcSEcCtD
Lidocaine—Hypotension—Betamethasone—psoriasis	5.22e-05	0.000344	CcSEcCtD
Lidocaine—Hypotension—Dexamethasone—psoriasis	5.22e-05	0.000344	CcSEcCtD
Lidocaine—Urticaria—Hydrocortisone—psoriasis	5.19e-05	0.000343	CcSEcCtD
Lidocaine—Angiopathy—Methotrexate—psoriasis	5.19e-05	0.000343	CcSEcCtD
Lidocaine—Immune system disorder—Methotrexate—psoriasis	5.17e-05	0.000341	CcSEcCtD
Lidocaine—Convulsion—Prednisone—psoriasis	5.16e-05	0.000341	CcSEcCtD
Lidocaine—Asthenia—Mycophenolate mofetil—psoriasis	5.15e-05	0.00034	CcSEcCtD
Lidocaine—Hypertension—Prednisone—psoriasis	5.15e-05	0.000339	CcSEcCtD
Lidocaine—Chills—Methotrexate—psoriasis	5.13e-05	0.000339	CcSEcCtD
Lidocaine—Feeling abnormal—Triamcinolone—psoriasis	5.07e-05	0.000335	CcSEcCtD
Lidocaine—Anxiety—Prednisone—psoriasis	5.06e-05	0.000334	CcSEcCtD
Lidocaine—Paraesthesia—Dexamethasone—psoriasis	5.02e-05	0.000331	CcSEcCtD
Lidocaine—Paraesthesia—Betamethasone—psoriasis	5.02e-05	0.000331	CcSEcCtD
Lidocaine—Erythema—Methotrexate—psoriasis	4.98e-05	0.000329	CcSEcCtD
Lidocaine—Hypersensitivity—Prednisolone—psoriasis	4.93e-05	0.000325	CcSEcCtD
Lidocaine—Urticaria—Triamcinolone—psoriasis	4.89e-05	0.000323	CcSEcCtD
Lidocaine—Dysgeusia—Methotrexate—psoriasis	4.88e-05	0.000322	CcSEcCtD
Lidocaine—Dizziness—Cyclosporine—psoriasis	4.87e-05	0.000321	CcSEcCtD
Lidocaine—Anaphylactic shock—Prednisone—psoriasis	4.86e-05	0.000321	CcSEcCtD
Lidocaine—Oedema—Prednisone—psoriasis	4.86e-05	0.000321	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Dexamethasone—psoriasis	4.82e-05	0.000318	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Betamethasone—psoriasis	4.82e-05	0.000318	CcSEcCtD
Lidocaine—Back pain—Methotrexate—psoriasis	4.82e-05	0.000318	CcSEcCtD
Lidocaine—Hypersensitivity—Hydrocortisone—psoriasis	4.82e-05	0.000318	CcSEcCtD
Lidocaine—Shock—Prednisone—psoriasis	4.79e-05	0.000316	CcSEcCtD
Lidocaine—Pain—Betamethasone—psoriasis	4.78e-05	0.000315	CcSEcCtD
Lidocaine—Pain—Dexamethasone—psoriasis	4.78e-05	0.000315	CcSEcCtD
Lidocaine—Nervous system disorder—Prednisone—psoriasis	4.77e-05	0.000315	CcSEcCtD
Lidocaine—Dizziness—Mycophenolate mofetil—psoriasis	4.75e-05	0.000313	CcSEcCtD
Lidocaine—Hyperhidrosis—Prednisone—psoriasis	4.7e-05	0.00031	CcSEcCtD
Lidocaine—Vision blurred—Methotrexate—psoriasis	4.7e-05	0.00031	CcSEcCtD
Lidocaine—Asthenia—Hydrocortisone—psoriasis	4.69e-05	0.000309	CcSEcCtD
Lidocaine—Vomiting—Cyclosporine—psoriasis	4.68e-05	0.000309	CcSEcCtD
Lidocaine—Rash—Cyclosporine—psoriasis	4.64e-05	0.000306	CcSEcCtD
Lidocaine—Dermatitis—Cyclosporine—psoriasis	4.63e-05	0.000306	CcSEcCtD
Lidocaine—Headache—Cyclosporine—psoriasis	4.61e-05	0.000304	CcSEcCtD
Lidocaine—Feeling abnormal—Betamethasone—psoriasis	4.6e-05	0.000304	CcSEcCtD
Lidocaine—Feeling abnormal—Dexamethasone—psoriasis	4.6e-05	0.000304	CcSEcCtD
Lidocaine—Vomiting—Mycophenolate mofetil—psoriasis	4.56e-05	0.000301	CcSEcCtD
Lidocaine—Hypersensitivity—Triamcinolone—psoriasis	4.54e-05	0.000299	CcSEcCtD
Lidocaine—Rash—Mycophenolate mofetil—psoriasis	4.53e-05	0.000299	CcSEcCtD
Lidocaine—Dermatitis—Mycophenolate mofetil—psoriasis	4.52e-05	0.000298	CcSEcCtD
Lidocaine—Headache—Mycophenolate mofetil—psoriasis	4.5e-05	0.000297	CcSEcCtD
Lidocaine—Urticaria—Betamethasone—psoriasis	4.44e-05	0.000293	CcSEcCtD
Lidocaine—Urticaria—Dexamethasone—psoriasis	4.44e-05	0.000293	CcSEcCtD
Lidocaine—Dizziness—Prednisolone—psoriasis	4.43e-05	0.000292	CcSEcCtD
Lidocaine—Asthenia—Triamcinolone—psoriasis	4.42e-05	0.000291	CcSEcCtD
Lidocaine—Nausea—Cyclosporine—psoriasis	4.37e-05	0.000288	CcSEcCtD
Lidocaine—Paraesthesia—Prednisone—psoriasis	4.37e-05	0.000288	CcSEcCtD
Lidocaine—Dizziness—Hydrocortisone—psoriasis	4.32e-05	0.000285	CcSEcCtD
Lidocaine—Convulsion—Methotrexate—psoriasis	4.32e-05	0.000285	CcSEcCtD
Lidocaine—Nausea—Mycophenolate mofetil—psoriasis	4.26e-05	0.000281	CcSEcCtD
Lidocaine—Chest pain—Methotrexate—psoriasis	4.24e-05	0.00028	CcSEcCtD
Lidocaine—Rash—Prednisolone—psoriasis	4.22e-05	0.000278	CcSEcCtD
Lidocaine—Dermatitis—Prednisolone—psoriasis	4.22e-05	0.000278	CcSEcCtD
Lidocaine—Headache—Prednisolone—psoriasis	4.19e-05	0.000277	CcSEcCtD
Lidocaine—Vomiting—Hydrocortisone—psoriasis	4.16e-05	0.000274	CcSEcCtD
Lidocaine—Rash—Hydrocortisone—psoriasis	4.12e-05	0.000272	CcSEcCtD
Lidocaine—Dermatitis—Hydrocortisone—psoriasis	4.12e-05	0.000272	CcSEcCtD
Lidocaine—Confusional state—Methotrexate—psoriasis	4.1e-05	0.00027	CcSEcCtD
Lidocaine—Headache—Hydrocortisone—psoriasis	4.1e-05	0.00027	CcSEcCtD
Lidocaine—Dizziness—Triamcinolone—psoriasis	4.07e-05	0.000269	CcSEcCtD
Lidocaine—Anaphylactic shock—Methotrexate—psoriasis	4.07e-05	0.000268	CcSEcCtD
Lidocaine—Feeling abnormal—Prednisone—psoriasis	4.01e-05	0.000264	CcSEcCtD
Lidocaine—Asthenia—Dexamethasone—psoriasis	4.01e-05	0.000264	CcSEcCtD
Lidocaine—Asthenia—Betamethasone—psoriasis	4.01e-05	0.000264	CcSEcCtD
Lidocaine—Nervous system disorder—Methotrexate—psoriasis	3.99e-05	0.000263	CcSEcCtD
Lidocaine—Nausea—Prednisolone—psoriasis	3.98e-05	0.000262	CcSEcCtD
Lidocaine—Hyperhidrosis—Methotrexate—psoriasis	3.93e-05	0.000259	CcSEcCtD
Lidocaine—Vomiting—Triamcinolone—psoriasis	3.91e-05	0.000258	CcSEcCtD
Lidocaine—Nausea—Hydrocortisone—psoriasis	3.88e-05	0.000256	CcSEcCtD
Lidocaine—Rash—Triamcinolone—psoriasis	3.88e-05	0.000256	CcSEcCtD
Lidocaine—Dermatitis—Triamcinolone—psoriasis	3.88e-05	0.000256	CcSEcCtD
Lidocaine—Urticaria—Prednisone—psoriasis	3.86e-05	0.000255	CcSEcCtD
Lidocaine—Headache—Triamcinolone—psoriasis	3.86e-05	0.000254	CcSEcCtD
Lidocaine—Hypotension—Methotrexate—psoriasis	3.8e-05	0.000251	CcSEcCtD
Lidocaine—Dizziness—Dexamethasone—psoriasis	3.69e-05	0.000244	CcSEcCtD
Lidocaine—Dizziness—Betamethasone—psoriasis	3.69e-05	0.000244	CcSEcCtD
Lidocaine—Nausea—Triamcinolone—psoriasis	3.66e-05	0.000241	CcSEcCtD
Lidocaine—Paraesthesia—Methotrexate—psoriasis	3.65e-05	0.000241	CcSEcCtD
Lidocaine—Dyspnoea—Methotrexate—psoriasis	3.62e-05	0.000239	CcSEcCtD
Lidocaine—Somnolence—Methotrexate—psoriasis	3.61e-05	0.000238	CcSEcCtD
Lidocaine—Hypersensitivity—Prednisone—psoriasis	3.58e-05	0.000236	CcSEcCtD
Lidocaine—Vomiting—Betamethasone—psoriasis	3.55e-05	0.000234	CcSEcCtD
Lidocaine—Vomiting—Dexamethasone—psoriasis	3.55e-05	0.000234	CcSEcCtD
Lidocaine—Rash—Betamethasone—psoriasis	3.52e-05	0.000232	CcSEcCtD
Lidocaine—Rash—Dexamethasone—psoriasis	3.52e-05	0.000232	CcSEcCtD
Lidocaine—Dermatitis—Dexamethasone—psoriasis	3.52e-05	0.000232	CcSEcCtD
Lidocaine—Dermatitis—Betamethasone—psoriasis	3.52e-05	0.000232	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Methotrexate—psoriasis	3.51e-05	0.000232	CcSEcCtD
Lidocaine—Headache—Betamethasone—psoriasis	3.5e-05	0.000231	CcSEcCtD
Lidocaine—Headache—Dexamethasone—psoriasis	3.5e-05	0.000231	CcSEcCtD
Lidocaine—Asthenia—Prednisone—psoriasis	3.49e-05	0.00023	CcSEcCtD
Lidocaine—Pain—Methotrexate—psoriasis	3.48e-05	0.000229	CcSEcCtD
Lidocaine—Feeling abnormal—Methotrexate—psoriasis	3.35e-05	0.000221	CcSEcCtD
Lidocaine—Nausea—Betamethasone—psoriasis	3.32e-05	0.000219	CcSEcCtD
Lidocaine—Nausea—Dexamethasone—psoriasis	3.32e-05	0.000219	CcSEcCtD
Lidocaine—Urticaria—Methotrexate—psoriasis	3.23e-05	0.000213	CcSEcCtD
Lidocaine—Dizziness—Prednisone—psoriasis	3.22e-05	0.000212	CcSEcCtD
Lidocaine—Vomiting—Prednisone—psoriasis	3.09e-05	0.000204	CcSEcCtD
Lidocaine—Rash—Prednisone—psoriasis	3.07e-05	0.000202	CcSEcCtD
Lidocaine—Dermatitis—Prednisone—psoriasis	3.06e-05	0.000202	CcSEcCtD
Lidocaine—Headache—Prednisone—psoriasis	3.05e-05	0.000201	CcSEcCtD
Lidocaine—Hypersensitivity—Methotrexate—psoriasis	3e-05	0.000198	CcSEcCtD
Lidocaine—Asthenia—Methotrexate—psoriasis	2.92e-05	0.000192	CcSEcCtD
Lidocaine—Nausea—Prednisone—psoriasis	2.89e-05	0.000191	CcSEcCtD
Lidocaine—EGFR—MAPK Signaling Pathway—JUN—psoriasis	2.75e-05	0.000595	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—NFKB1—psoriasis	2.74e-05	0.000592	CbGpPWpGaD
Lidocaine—EGFR—Signaling by SCF-KIT—STAT3—psoriasis	2.74e-05	0.000592	CbGpPWpGaD
Lidocaine—EGFR—Spinal Cord Injury—TNF—psoriasis	2.73e-05	0.000591	CbGpPWpGaD
Lidocaine—ABCB1—Allograft Rejection—CXCL8—psoriasis	2.73e-05	0.00059	CbGpPWpGaD
Lidocaine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	2.73e-05	0.00059	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—CYP2S1—psoriasis	2.72e-05	0.000587	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—NFKBIA—psoriasis	2.71e-05	0.000586	CbGpPWpGaD
Lidocaine—SCN5A—SIDS Susceptibility Pathways—IL6—psoriasis	2.69e-05	0.000582	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—HLA-E—psoriasis	2.69e-05	0.000582	CbGpPWpGaD
Lidocaine—Dizziness—Methotrexate—psoriasis	2.69e-05	0.000177	CcSEcCtD
Lidocaine—EGFR—Downstream signaling events of B Cell Receptor (BCR)—NFKB1—psoriasis	2.66e-05	0.000575	CbGpPWpGaD
Lidocaine—EGFR—MAPK Signaling Pathway—NFKB1—psoriasis	2.65e-05	0.000572	CbGpPWpGaD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—JUN—psoriasis	2.64e-05	0.00057	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—NFKB1—psoriasis	2.62e-05	0.000566	CbGpPWpGaD
Lidocaine—EGFR—Integrated Breast Cancer Pathway—VEGFA—psoriasis	2.62e-05	0.000566	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—CCL20—psoriasis	2.6e-05	0.000563	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—HLA-E—psoriasis	2.59e-05	0.000559	CbGpPWpGaD
Lidocaine—Vomiting—Methotrexate—psoriasis	2.59e-05	0.000171	CcSEcCtD
Lidocaine—CYP2B6—Metabolism—NDUFA5—psoriasis	2.58e-05	0.000557	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TAGAP—psoriasis	2.57e-05	0.000555	CbGpPWpGaD
Lidocaine—Rash—Methotrexate—psoriasis	2.56e-05	0.000169	CcSEcCtD
Lidocaine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	2.56e-05	0.000554	CbGpPWpGaD
Lidocaine—Dermatitis—Methotrexate—psoriasis	2.56e-05	0.000169	CcSEcCtD
Lidocaine—Headache—Methotrexate—psoriasis	2.55e-05	0.000168	CcSEcCtD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—NFKB1—psoriasis	2.54e-05	0.000549	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—NDUFA5—psoriasis	2.52e-05	0.000545	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—NFKB1—psoriasis	2.52e-05	0.000544	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—NFKB1—psoriasis	2.52e-05	0.000544	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—PPARG—psoriasis	2.5e-05	0.00054	CbGpPWpGaD
Lidocaine—EGFR—Focal Adhesion—JUN—psoriasis	2.49e-05	0.000539	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—VEGFA—psoriasis	2.49e-05	0.000537	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.48e-05	0.000537	CbGpPWpGaD
Lidocaine—EGFR—Downstream signal transduction—STAT3—psoriasis	2.46e-05	0.000532	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—STAT3—psoriasis	2.46e-05	0.000532	CbGpPWpGaD
Lidocaine—EGFR—EGF/EGFR Signaling Pathway—STAT3—psoriasis	2.45e-05	0.00053	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—NFKB1—psoriasis	2.43e-05	0.000525	CbGpPWpGaD
Lidocaine—Nausea—Methotrexate—psoriasis	2.42e-05	0.000159	CcSEcCtD
Lidocaine—SCN9A—Axon guidance—IL6—psoriasis	2.41e-05	0.000521	CbGpPWpGaD
Lidocaine—EGFR—Spinal Cord Injury—TP53—psoriasis	2.41e-05	0.000521	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.39e-05	0.000517	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—VEGFA—psoriasis	2.38e-05	0.000514	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—STAT3—psoriasis	2.36e-05	0.000509	CbGpPWpGaD
Lidocaine—EGFR—B Cell Activation—NFKB1—psoriasis	2.35e-05	0.000508	CbGpPWpGaD
Lidocaine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.34e-05	0.000506	CbGpPWpGaD
Lidocaine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.34e-05	0.000506	CbGpPWpGaD
Lidocaine—SCN3A—Axon guidance—IL6—psoriasis	2.31e-05	0.000498	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—VEGFA—psoriasis	2.29e-05	0.000494	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—VEGFA—psoriasis	2.29e-05	0.000494	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR in disease—STAT3—psoriasis	2.28e-05	0.000493	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—STAT3—psoriasis	2.26e-05	0.000489	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—STAT3—psoriasis	2.26e-05	0.000489	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2.25e-05	0.000486	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—SOCS1—psoriasis	2.25e-05	0.000486	CbGpPWpGaD
Lidocaine—EGFR—Signaling by PDGF—STAT3—psoriasis	2.23e-05	0.000483	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—TYK2—psoriasis	2.22e-05	0.00048	CbGpPWpGaD
Lidocaine—ABCB1—Allograft Rejection—VEGFA—psoriasis	2.22e-05	0.00048	CbGpPWpGaD
Lidocaine—SCN2A—Axon guidance—IL6—psoriasis	2.22e-05	0.000479	CbGpPWpGaD
Lidocaine—SCN4A—Axon guidance—IL6—psoriasis	2.22e-05	0.000479	CbGpPWpGaD
Lidocaine—EGFR—Spinal Cord Injury—IL6—psoriasis	2.21e-05	0.000477	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—VEGFA—psoriasis	2.2e-05	0.000476	CbGpPWpGaD
Lidocaine—EGFR—Immune System—ITGAL—psoriasis	2.2e-05	0.000475	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—CYP2S1—psoriasis	2.19e-05	0.000474	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—TYK2—psoriasis	2.19e-05	0.000474	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—NDUFA5—psoriasis	2.18e-05	0.000472	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—STAT3—psoriasis	2.18e-05	0.000472	CbGpPWpGaD
Lidocaine—EGFR—Focal Adhesion—VEGFA—psoriasis	2.18e-05	0.000471	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—CARM1—psoriasis	2.18e-05	0.000471	CbGpPWpGaD
Lidocaine—SCN5A—Axon guidance—VEGFA—psoriasis	2.17e-05	0.000469	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.17e-05	0.000469	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—SOCS1—psoriasis	2.16e-05	0.000467	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CYP2S1—psoriasis	2.14e-05	0.000463	CbGpPWpGaD
Lidocaine—SCN10A—Axon guidance—IL6—psoriasis	2.14e-05	0.000462	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—TNF—psoriasis	2.13e-05	0.000461	CbGpPWpGaD
Lidocaine—EGFR—Direct p53 effectors—TP53—psoriasis	2.1e-05	0.000454	CbGpPWpGaD
Lidocaine—EGFR—MAPK Signaling Pathway—TNF—psoriasis	2.06e-05	0.000445	CbGpPWpGaD
Lidocaine—EGFR—Immune System—REL—psoriasis	2.05e-05	0.000444	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—TNF—psoriasis	2.04e-05	0.000441	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.03e-05	0.00044	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	2.02e-05	0.000437	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—TYK2—psoriasis	2.01e-05	0.000434	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IFIH1—psoriasis	1.99e-05	0.000431	CbGpPWpGaD
Lidocaine—EGFR—Integrated Breast Cancer Pathway—TP53—psoriasis	1.98e-05	0.000428	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—TNF—psoriasis	1.96e-05	0.000423	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—TNF—psoriasis	1.96e-05	0.000423	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—HLA-B—psoriasis	1.92e-05	0.000415	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—CD8A—psoriasis	1.92e-05	0.000414	CbGpPWpGaD
Lidocaine—EGFR—Signaling by SCF-KIT—IL6—psoriasis	1.91e-05	0.000413	CbGpPWpGaD
Lidocaine—ABCB1—Allograft Rejection—TNF—psoriasis	1.9e-05	0.000411	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—NDUFA5—psoriasis	1.9e-05	0.000411	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.89e-05	0.000409	CbGpPWpGaD
Lidocaine—EGFR—Immune System—HLA-C—psoriasis	1.89e-05	0.000408	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—TNF—psoriasis	1.89e-05	0.000408	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—LEP—psoriasis	1.88e-05	0.000406	CbGpPWpGaD
Lidocaine—EGFR—Immune System—TNFAIP3—psoriasis	1.87e-05	0.000403	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.86e-05	0.000402	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CYP2S1—psoriasis	1.86e-05	0.000401	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—HLA-B—psoriasis	1.84e-05	0.000398	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling of activated FGFR—IL6—psoriasis	1.83e-05	0.000396	CbGpPWpGaD
Lidocaine—EGFR—MAPK Signaling Pathway—TP53—psoriasis	1.82e-05	0.000393	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB4—IL6—psoriasis	1.8e-05	0.000389	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—NDUFA5—psoriasis	1.79e-05	0.000387	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—NDUFA5—psoriasis	1.78e-05	0.000384	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.77e-05	0.000382	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—NFKB1—psoriasis	1.73e-05	0.000374	CbGpPWpGaD
Lidocaine—EGFR—Downstream signal transduction—IL6—psoriasis	1.72e-05	0.000372	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—IL6—psoriasis	1.72e-05	0.000372	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR—IL6—psoriasis	1.71e-05	0.00037	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—HLA-A—psoriasis	1.71e-05	0.000369	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—NFKB1—psoriasis	1.71e-05	0.000369	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB2—IL6—psoriasis	1.7e-05	0.000368	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—CRP—psoriasis	1.7e-05	0.000367	CbGpPWpGaD
Lidocaine—EGFR—DAP12 signaling—IL6—psoriasis	1.7e-05	0.000366	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.69e-05	0.000364	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.66e-05	0.000358	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—IL6—psoriasis	1.65e-05	0.000356	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.64e-05	0.000354	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—PPARG—psoriasis	1.64e-05	0.000354	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CYP2S1—psoriasis	1.62e-05	0.000349	CbGpPWpGaD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	1.59e-05	0.000345	CbGpPWpGaD
Lidocaine—EGFR—DAP12 interactions—IL6—psoriasis	1.59e-05	0.000345	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR in disease—IL6—psoriasis	1.59e-05	0.000345	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—IL6—psoriasis	1.58e-05	0.000342	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—IL6—psoriasis	1.58e-05	0.000342	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR—IL6—psoriasis	1.58e-05	0.000342	CbGpPWpGaD
Lidocaine—EGFR—Immune System—HLA-E—psoriasis	1.57e-05	0.000339	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR in Cancer—IL6—psoriasis	1.57e-05	0.000339	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—HLA-DRB1—psoriasis	1.56e-05	0.000337	CbGpPWpGaD
Lidocaine—EGFR—Signaling by PDGF—IL6—psoriasis	1.56e-05	0.000337	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—STAT3—psoriasis	1.56e-05	0.000336	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—VEGFA—psoriasis	1.55e-05	0.000335	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—NFKBIA—psoriasis	1.55e-05	0.000334	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CCL20—psoriasis	1.54e-05	0.000332	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—STAT3—psoriasis	1.53e-05	0.000332	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—IL6—psoriasis	1.52e-05	0.000329	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CYP2S1—psoriasis	1.52e-05	0.000329	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—NDUFA5—psoriasis	1.52e-05	0.000328	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CYP2S1—psoriasis	1.51e-05	0.000326	CbGpPWpGaD
Lidocaine—SCN5A—Axon guidance—IL6—psoriasis	1.5e-05	0.000325	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—ICAM1—psoriasis	1.5e-05	0.000324	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—NFKBIA—psoriasis	1.49e-05	0.000321	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—CARM1—psoriasis	1.45e-05	0.000313	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—TYK2—psoriasis	1.43e-05	0.00031	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—VEGFA—psoriasis	1.42e-05	0.000307	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.42e-05	0.000306	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	1.41e-05	0.000305	CbGpPWpGaD
Lidocaine—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.36e-05	0.000295	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—CAT—psoriasis	1.34e-05	0.000289	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—TNF—psoriasis	1.33e-05	0.000287	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—CARM1—psoriasis	1.33e-05	0.000287	CbGpPWpGaD
Lidocaine—EGFR—Immune System—SOCS1—psoriasis	1.31e-05	0.000283	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CYP2S1—psoriasis	1.29e-05	0.000279	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—TYK2—psoriasis	1.27e-05	0.000274	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.25e-05	0.000271	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.21e-05	0.000261	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—NDUFA5—psoriasis	1.17e-05	0.000253	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CD8A—psoriasis	1.16e-05	0.000251	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—CD4—psoriasis	1.15e-05	0.000248	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—NFKB1—psoriasis	1.12e-05	0.000242	CbGpPWpGaD
Lidocaine—EGFR—Immune System—HLA-B—psoriasis	1.12e-05	0.000242	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—CD4—psoriasis	1.1e-05	0.000238	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.1e-05	0.000237	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—IL6—psoriasis	1.09e-05	0.000235	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—IL6—psoriasis	1.07e-05	0.000232	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—CARM1—psoriasis	1.07e-05	0.000231	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CARM1—psoriasis	1.05e-05	0.000226	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—APOE—psoriasis	1.04e-05	0.000225	CbGpPWpGaD
Lidocaine—EGFR—Immune System—HLA-A—psoriasis	1.04e-05	0.000224	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—JUN—psoriasis	1.03e-05	0.000222	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—VEGFA—psoriasis	1.01e-05	0.000219	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—STAT3—psoriasis	1e-05	0.000217	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CYP2S1—psoriasis	9.96e-06	0.000215	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CRP—psoriasis	9.88e-06	0.000214	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—NFKB1—psoriasis	9.87e-06	0.000213	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—IL6—psoriasis	9.83e-06	0.000212	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.73e-06	0.00021	CbGpPWpGaD
Lidocaine—EGFR—Disease—HLA-A—psoriasis	9.56e-06	0.000207	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—NFKB1—psoriasis	9.48e-06	0.000205	CbGpPWpGaD
Lidocaine—EGFR—Immune System—HLA-DRB1—psoriasis	9.46e-06	0.000204	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	9.39e-06	0.000203	CbGpPWpGaD
Lidocaine—EGFR—Immune System—ICAM1—psoriasis	9.08e-06	0.000196	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PPARG—psoriasis	9.06e-06	0.000196	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CARM1—psoriasis	9.06e-06	0.000196	CbGpPWpGaD
Lidocaine—EGFR—Immune System—NFKBIA—psoriasis	9.01e-06	0.000195	CbGpPWpGaD
Lidocaine—EGFR—Disease—APOE—psoriasis	8.93e-06	0.000193	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—CAT—psoriasis	8.9e-06	0.000192	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—TNF—psoriasis	8.69e-06	0.000188	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.47e-06	0.000183	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—SOCS1—psoriasis	8.47e-06	0.000183	CbGpPWpGaD
Lidocaine—EGFR—Disease—NOS2—psoriasis	8.32e-06	0.00018	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	8.27e-06	0.000179	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—CAT—psoriasis	8.16e-06	0.000176	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—TYK2—psoriasis	8.08e-06	0.000175	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.91e-06	0.000171	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CARM1—psoriasis	7.9e-06	0.000171	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CARM1—psoriasis	7.44e-06	0.000161	CbGpPWpGaD
Lidocaine—EGFR—Immune System—TYK2—psoriasis	7.38e-06	0.000159	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CARM1—psoriasis	7.38e-06	0.000159	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—CXCL8—psoriasis	7.03e-06	0.000152	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—IL6—psoriasis	7.02e-06	0.000152	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—APOE—psoriasis	6.92e-06	0.000149	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IFNG—psoriasis	6.91e-06	0.000149	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.89e-06	0.000149	CbGpPWpGaD
Lidocaine—EGFR—Disease—TYK2—psoriasis	6.81e-06	0.000147	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.76e-06	0.000146	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CD4—psoriasis	6.67e-06	0.000144	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—CAT—psoriasis	6.58e-06	0.000142	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CAT—psoriasis	6.44e-06	0.000139	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—APOE—psoriasis	6.34e-06	0.000137	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CARM1—psoriasis	6.3e-06	0.000136	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—LEP—psoriasis	6.25e-06	0.000135	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—APOE—psoriasis	6.25e-06	0.000135	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—IL6—psoriasis	6.2e-06	0.000134	CbGpPWpGaD
Lidocaine—EGFR—Disease—CD4—psoriasis	6.16e-06	0.000133	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PPARG—psoriasis	6.03e-06	0.00013	CbGpPWpGaD
Lidocaine—EGFR—Immune System—JUN—psoriasis	5.97e-06	0.000129	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.89e-06	0.000127	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—NFKBIA—psoriasis	5.82e-06	0.000126	CbGpPWpGaD
Lidocaine—EGFR—Immune System—NFKB1—psoriasis	5.75e-06	0.000124	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CAT—psoriasis	5.57e-06	0.00012	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PPARG—psoriasis	5.52e-06	0.000119	CbGpPWpGaD
Lidocaine—EGFR—Immune System—STAT3—psoriasis	5.17e-06	0.000112	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—APOE—psoriasis	5.12e-06	0.000111	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—APOE—psoriasis	5e-06	0.000108	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CARM1—psoriasis	4.86e-06	0.000105	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CAT—psoriasis	4.86e-06	0.000105	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TYK2—psoriasis	4.77e-06	0.000103	CbGpPWpGaD
Lidocaine—EGFR—Disease—STAT3—psoriasis	4.77e-06	0.000103	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CAT—psoriasis	4.58e-06	9.89e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CAT—psoriasis	4.54e-06	9.8e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PPARG—psoriasis	4.46e-06	9.63e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PPARG—psoriasis	4.36e-06	9.41e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—APOE—psoriasis	4.33e-06	9.36e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CXCL8—psoriasis	4.15e-06	8.98e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—IL6—psoriasis	3.95e-06	8.54e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CAT—psoriasis	3.88e-06	8.38e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—JUN—psoriasis	3.86e-06	8.35e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—APOE—psoriasis	3.77e-06	8.15e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PPARG—psoriasis	3.77e-06	8.15e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—NFKB1—psoriasis	3.72e-06	8.03e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IL6—psoriasis	3.61e-06	7.8e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—APOE—psoriasis	3.56e-06	7.68e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—APOE—psoriasis	3.52e-06	7.62e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—VEGFA—psoriasis	3.37e-06	7.29e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—STAT3—psoriasis	3.34e-06	7.22e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—IL6—psoriasis	3.33e-06	7.2e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PPARG—psoriasis	3.29e-06	7.1e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PPARG—psoriasis	3.1e-06	6.69e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PPARG—psoriasis	3.07e-06	6.64e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—APOE—psoriasis	3.01e-06	6.51e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CAT—psoriasis	2.99e-06	6.47e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PPARG—psoriasis	2.62e-06	5.67e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TP53—psoriasis	2.55e-06	5.51e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IL6—psoriasis	2.33e-06	5.04e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—APOE—psoriasis	2.32e-06	5.02e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PPARG—psoriasis	2.02e-06	4.38e-05	CbGpPWpGaD
